Form 4: Vaxcyte Director Teri Loxam Granted Equity Awards, Aligning Interests with Shareholders

Vaxcyte, Inc. Director Teri Loxam was granted 3,041 Restricted Stock Units (RSUs) and options to purchase 15,372 shares of common stock, aligning her compensation with company performance.

Summary

• Vaxcyte, Inc. Director Teri Loxam acquired 3,041 shares of Common Stock through Restricted Stock Units (RSUs) on June 12, 2025.
• Each RSU represents the contingent right to receive one share of Vaxcyte's Common Stock.
• These RSUs will fully vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, contingent on continuous service.
• Following this transaction, Teri Loxam beneficially owns 10,216 shares of Common Stock.
• Additionally, Ms. Loxam acquired options to purchase 15,372 shares of Common Stock with an exercise price of $34.46 per share on June 12, 2025.
• These stock options will vest monthly and fully vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, contingent on continuous service.
• The stock options have an expiration date of June 12, 2035.
• Following this transaction, Teri Loxam beneficially owns 15,372 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates standard compensation practices that align director interests with shareholders, without any negative implications from the filing itself.

Positives

• The grant of Restricted Stock Units and stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

The document details future vesting schedules for equity awards, indicating that the RSUs and stock options will fully vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, subject to continuous service.

Industry Context

The granting of equity awards to directors is a common practice across various industries, particularly in the biotechnology and pharmaceutical sectors, to align leadership incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with vesting schedules tied to continued service, is a standard practice for director compensation in publicly traded companies, especially within the biotech industry.
• The vesting period of approximately one year (until June 12, 2026) is typical for annual director equity grants, designed to retain talent and encourage sustained commitment.

Related Party Transactions

• The transaction involves the grant of equity awards (RSUs and stock options) to Teri Loxam, a director of Vaxcyte, Inc., which is a common form of compensation for related parties (insiders).

Stakeholder Impact

• Shareholders: The equity grants align the director's financial incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The RSUs and stock options will vest monthly and fully vest on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, subject to Teri Loxam's continuous service.

Key Dates

Keywords

Vaxcyte, PCVX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Option, Director Compensation, Beneficial Ownership